ANN ARBOR, MI / ACCESSWIRE / January 24, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or "Company") announced today that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023.
Company Webcast
The Company's webcast presentation will be available for viewing at 9:00am ET on Tuesday, January 31, 2023, at https://wsw.com/webcast/lytham7/zom/1898244, and subsequently on the Company's website at www.ZOMEDICA.com.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it. or register at https://www.lythampartners.com/winter2023invreg/.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Contacts
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.07 |
| Daily Change: | -0.0003 -0.41 |
| Daily Volume: | 388,327 |
| Market Cap: | US$70.560M |
October 23, 2025 October 14, 2025 October 09, 2025 September 23, 2025 September 18, 2025 | |

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load